These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 14681961)

  • 1. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):21-4. PubMed ID: 14681961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of Parkinson's disease: use of piribedil].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(1):54-6. PubMed ID: 14870695
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of piribedil in early and late stages of Parkinson's disease].
    Fedorova NV; Kulua TK; Gubanova ЕN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):96-98. PubMed ID: 26525631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral edema and dopamine agonists in Parkinson disease.
    Tan EK
    Arch Neurol; 2007 Oct; 64(10):1546-7; author reply 1547. PubMed ID: 17923645
    [No Abstract]   [Full Text] [Related]  

  • 9. [Idiopathic Parkinson's disease: practical hints for the treatment].
    Ludin HP
    Praxis (Bern 1994); 2005 Jul; 94(30-31):1147-50. PubMed ID: 16117469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep attacks and Parkinson's disease treatment.
    Ferreira JJ; Galitzky M; Montastruc JL; Rascol O
    Lancet; 2000 Apr; 355(9212):1333-4. PubMed ID: 10776750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):83-90. PubMed ID: 28745677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Association between amytrophic lateral sclerosis and Parkinson's disease].
    Alonso-Navarro H; Ruiz-Ezquerro JJ; Adeva-Bartolomé T; Jiménez-Jiménez FJ
    Med Clin (Barc); 2007 Oct; 129(12):478-9. PubMed ID: 17953916
    [No Abstract]   [Full Text] [Related]  

  • 13. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
    Callaghan N; Fitzpatrick E; O'Mahony JB
    Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
    Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
    Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medical treatment of Parkinson's disease].
    Waldvogel D
    Ther Umsch; 2007 Jan; 64(1):15-20. PubMed ID: 17221820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delusional infestation induced by piribedil add-on in Parkinson's disease.
    Kölle M; Lepping P; Kassubek J; Schönfeldt-Lecuona C; Freudenmann RW
    Pharmacopsychiatry; 2010 Aug; 43(6):240-2. PubMed ID: 20614418
    [No Abstract]   [Full Text] [Related]  

  • 17. The Efficacy and Safety of Piribedil Relative to Pramipexole for the Treatment of Early Parkinson Disease: A Systematic Literature Review and Network Meta-Analysis.
    Chen X; Ren C; Li J; Wang S; Dron L; Harari O; Whittington C
    Clin Neuropharmacol; 2020; 43(4):100-106. PubMed ID: 32658035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 19. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term efficacy of rasagiline in early Parkinson's disease.
    Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ
    Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.